American Heart Journal
Volume 157, Issue 2 , Pages 369-374, February 2009

Bleeding risk associated with 1 year of dual antiplatelet therapy after percutaneous coronary intervention: Insights from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial

  • Herbert D. Aronow, MD, MPH

      Affiliations

    • Clinical Scholars Program, Michigan Heart and Vascular Institute at St. Joseph Mercy Hospital, Ann Arbor, MI
    • Corresponding Author InformationReprint requests: Herbert D. Aronow, MD, MPH, Michigan Heart, P.C., 5325 Elliott Dr., Suite #202, Ypsilanti, MI 48197.
    • ,
  • Steven R. Steinhubl, MD

      Affiliations

    • Division of Cardiology, University of Kentucky, Lexington, KY
    • ,
  • Danielle M. Brennan, MS

      Affiliations

    • Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH
    • ,
  • Peter B. Berger, MD

      Affiliations

    • Geisinger Clinic, Danville, PA
    • ,
  • Eric J. Topol, MD

      Affiliations

    • Division of Cardiovascular Diseases, Scripps Clinic, La Jolla, CA
    • ,
  • for the CREDO Investigators

Received 29 March 2008; accepted 14 September 2008. published online 03 November 2008.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 The CREDO trial was funded by Bristol-Myers Squibb (New York, NY)/Sanofi-Synthelabo (Paris, France) partnership. The study sponsors played no role in the design of this substudy, nor in the collection, analysis, or interpretation of these data.

 Dr. Aronow is on the Speakers' Bureau for and has received grant funding from Bristol-Myers Squibb-Sanofi. Ms. Brennan has no conflicts of interest to disclose. Drs Topol and Steinhubl received research grants from Sanofi-Aventis and Bristol-Myers Squibb to conduct the trial; Dr. Steinhubl served as a consultant to this company in the clinical development of clopidogrel. Dr Steinhubl is currently employed by the Medicines Company (Parsippany, NJ). Dr Berger has received honoraria for speaking at Bristol-Myers Squibb-Sanofi–sponsored symposia.

PII: S0002-8703(08)00805-3

doi:10.1016/j.ahj.2008.09.011

American Heart Journal
Volume 157, Issue 2 , Pages 369-374, February 2009

Article Tools

* Image Usage & Resolution